RNA Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (mRNA Therapeutics, RNA interference (RNAi), Antisense oligonucleotides, Others), By Application (Oncology, Infectious Diseases, Genetic Diseases, Ophthalmology, Cardiovascular Diseases, Others), By End User (Hospitals & Clinics, Research Institutes, Others) and By Country (U.S., Canada) Forecasts, 2026-2034

RNA Therapeutics Market Dynamics

Market Drivers

Surge in Incidences of Cancer and Genetic Diseases

The rise in prevalence of cancer and genetic diseases is creating a strong demand for advanced therapies.

• For instance, according to the American Cancer Society, more than 2 million new cancer cases were reported in the U.S. in 2024, significantly increasing the need for novel RNA therapies.

Additionally, rare genetic diseases are rapidly surging; Alnylam’s Onpattro, the first approved RNA therapy, addresses these medical needs. These developments show that a growing patient pool is driving the product adoption.

Strong Funding Support from the Government and Academic Institutes

Increasing funding from government and academic institutes is a major factor driving the market growth.

• For instance, in April 2025, the U.S. National Institute of Health announced more than USD 200 million in new grants for advancing RNAi-based platforms for cancer and rare diseases.

These funding activities show that the government is making RNA innovation a strategic priority, which is expanding manufacturing capacity and accelerating market growth.

Market Restraints

High Development and Manufacturing Costs

The increasing cost of developing novel RNA therapies is restraining the market growth to some extent. Manufacturing mRNA and RNAi treatments requires high-purity nucleotides, specialized enzymes, and lipid nanoparticles.

• For instance, according to NCBI, about 60% of the cost of producing mRNA drugs comes from raw materials, making the manufacturing process costly and impacting the development of RNA therapies.

Market Opportunities

Expanding Pipeline of mRNA and RNAi Therapies

Leading vaccine developers have shifted their focus from only vaccines to developing RNA-based treatments for cancer, rare diseases, and other metabolic diseases.

Table: Alnylam RNA Therapeutics Pipeline

Source: Company Annual Reports & Straits Analysis

 As more of these therapies move through clinical trials and gain approval, more treatment options will be available, making RNA therapeutics a major part of healthcare.

RNA Therapeutics Market Segmentation Analysis

By Type

The mRNA therapeutics dominated the market with a revenue share of 31.42% in 2025. This growth is attributed to the strong success rate of mRNA vaccines and the rapid expansion of these therapies in oncology and cardiovascular disease management. Moreover, robust investments across the research and development of mRNA therapies make it a dominant segment in the market.

Source: Straits Analysis

By Application

The oncology segment dominated the market in 2025 with a revenue share of 33.57% and is anticipated to register the fastest CAGR growth. The growth is attributed to rising global cancer burden, the strong potential of RNA-based targeted therapies, and continued advances in mRNA cancer vaccines, all of which are accelerating clinical uptake and pipeline investment.

By End User

The hospitals and clinics segment dominated the market in 2025, as these are the primary healthcare facilities for administering advanced mRNA vaccines and RNAi treatments. Additionally, the majority of the clinical trials and early access programs for RNA therapies are conducted in hospital settings, allowing faster access to novel drugs. These factors support segmental growth.

Regional Analysis

North America Market Trends

North America dominated the RNA therapeutics market in 2025, accounting for 43.79% market share. The growth is attributed to increased regulatory approvals and the development of novel RNA platforms. Furthermore, support from regulatory authorities also propels regional market growth. For instance, in 2024, the U.S. Food and Drug Administration (FDA) approved 21 RNA-based therapies, including mRNA vaccines and RNAi drug products. Moreover, the availability of robust infrastructure for product development and manufacturing also boosts market growth in the region.

U.S. accounts for the dominant share in the RNA therapeutics market, driven by increasing incidences of genetic and chronic diseases, robust R&D funding for developing novel RNA treatment approaches, advancements in synthetic biology and bioinformatics, and internal partnerships for product development.

• For instance, in August 2024, Sirnaomics entered a partnership with Gore Range for the establishment of a joint venture, Sagesse Bion, Inc., to advance its novel RNAi therapeutic products into aesthetic medicine.

Moreover, the FDA’s leadership in approving new RNA therapies bolsters manufacturers’ confidence to advance their pipelines.

Asia Pacific Market Trends

Asis Pacific is emerging as the fastest-growing region with a CAGR of 12.7% from 2026 to 2034, owing to increasing local innovations, expanding contract development and manufacturing organizations, and a surge in infrastructure investments. For instance, in June 2024, CSPC Pharmaceutical Group in China secured approval for SYS6020 as the world’s first mRNA-LNP-based cell therapy. It is a synthetic mRNA therapy developed to treat melanoma. Additionally, Innorna received the IND clearance in July 2024 from NMPA and the U.S. FDA for its Herpes Zoster mRNA vaccine. Such advances are positioning the Asia Pacific as the fastest-growing region in the RNA therapeutics industry.

China's RNA therapeutics market growth is driven by a rapid increase in clinical trials of mRNA and RNAi drugs, led by domestic manufacturers such as Stemirna Therapeutics and Suzhou Ribo Life Science. For instance, in 2023, Stemirna Therapeutics advanced its mRNA COVID-19 booster into the last stage of clinical trials. This showcases China’s ability to rapidly develop and scale mRNA vaccines. Moreover, the Chinese government has made biotechnology a priority in its five-year plan, which will enable rapid funding, infrastructure support, and regulatory approvals for RNA therapeutics.

In Japan, the RNA therapeutics industry is gaining momentum through joint ventures for developing RNA therapies, a focus on mRNA technologies, and strong government support for biotech industry development.

• For instance, in March 2024, Tokyo Medical and Dental University researchers developed chemically modified mRNA technologies for cancer vaccine development.
• Additionally, in April 2025, Ono Pharmaceuticals entered a partnership with U.S. startup Jorna Therapeutics to speed up the development of RNA therapies on Ono’s scale and Jorna’s technology.

Source: Straits Analysis

European Market Trends

Germany's market for RNA therapeutics growth is attributed to robust biotech firms and active support of the government sector through streamlining clinical research, offering funding for constructing advanced R&D facilities, and research. For instance, in June 2025, Neumirna Therapeutics secured USD 23 million in Series A funding for the development of RNA therapies to treat epilepsy and other neurological diseases.

Growth of the RNA therapeutics market in the UK is supported by a leading genomic research ecosystem and strong academic and industry collaborations. Additionally, the UK’s NHS framework supports the integration of advanced therapies into public healthcare with pilot programs testing mRNA vaccines for cancer patients directly in NHS hospitals. Thus, all aforementioned factors create a favorable environment for the growth of the RNA therapeutics market.